Compare Delta Air Lines, Inc. (DAL) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Moderna, Inc. — how do they compare? Delta Air Lines, Inc. trades at $90.1 (market cap $58.67B), while Moderna, Inc. trades at $60.53 (market cap $23.88B). The key difference: Delta Air Lines, Inc. is far larger — about 2.5× Moderna, Inc.'s market cap, and Delta Air Lines, Inc. pays a 0.87% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| DAL | MRNA | |
|---|---|---|
Market Cap | $58.67B | $23.88B |
Sector | Industrials | Health |
52-Week High | $93.66 | $81.80 |
52-Week Low | $55.65 | $22.36 |
Enterprise Value | $73.99B | $20.03B |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $91.34, down 0.7% today, amid a bullish technical trend and strong fundamentals. The stock shows robust earnings beats in recent quarters, with Q3 2026 EPS expected at $2.19. Valuation metrics like a P/E of 15.15 and P/S of 0.88 suggest potential undervaluation, while cash flow trends improved to a net positive $1.08B in 2025. Recent news highlights insider sales but also strong Q2 results and industry tailwinds.
Outlook remains positive with an 81.82% analyst buy rating and consensus price target of $108.27, implying ~18% upside. Key risks include fuel cost volatility and competitive pressures, but DAL's premium travel demand and loyalty program strength support growth. Investors should weigh solid fundamentals against macroeconomic sensitivities.
Moderna (MRNA) stock trades at $59.17, up 9.86% recently, with a bullish technical signal and strong institutional buying interest. The company's Q2 2026 earnings beat expectations, and the FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50+ marks a key post-pandemic milestone. However, fundamentals show declining revenue from $18.9B in 2022 to $1.9B in 2025 and persistent net losses, with a negative net income margin of -142.58% in 2025.
The outlook hinges on pipeline execution; while new vaccine approvals and cost-cutting efforts offer growth potential, the stock faces risks from high valuation multiples and ongoing profitability challenges. Analyst consensus is cautious with a $54.33 price target below the current price, reflecting mixed sentiment amid transitional phase uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
